Biosimilars in Dermatology: A Promising Solution to The High Cost of Biologic Therapy
Pharmaceutical Science-Dermatology
DOI:
https://doi.org/10.22376/ijlpr.2023.13.5.P110-P115Keywords:
biologic therapy, dermatological conditions, biosimilars, safety, cost-effectivenessAbstract
Biologic therapy has revolutionized the management of many chronic illnesses, including dermatological conditions.However, their high cost remains a significant barrier to global access for patients and healthcare systems. Biosimilars are highlysimilar versions of reference biologics that have the potential to provide comparable efficacy and safety at a lower cost. Theavailability of biosimilars in dermatology is increasing, and their impact on patient outcomes and healthcare systems is beingevaluated. Despite numerous reviews published on biosimilars, the literature needs a comprehensive and critical analysis of theiruse in dermatology. This review aims to address this lacuna by providing an up-to-date overview of the available evidence onbiosimilars in dermatology. This review evaluates biosimilars' efficacy, safety, and cost-effectiveness in dermatological conditions,including psoriasis, atopic dermatitis, and psoriatic arthritis. Our objective is to provide a comprehensive and critical analysis ofthe current evidence, identify knowledge gaps, and discuss biosimilars' potential impact on patient outcomes and healthcaresystems. We systematically reviewed the literature using several databases, including Medline, PubMed, Embase, and Scopus, toachieve our aim and objective. We included randomized controlled trials, systematic reviews, and observational studies thatevaluated the use of biosimilars in dermatology. Our review found that biosimilars are a promising solution to the high cost ofbiologic therapy in dermatology. Biosimilars have demonstrated comparable efficacy and safety to their reference biologics inseveral dermatological conditions. Furthermore, the cost-effectiveness of biosimilars is a significant advantage, allowing greateraccess to biologic therapy for patients and reducing the financial burden on healthcare systems.
References
Rho YH, Kim H, Lee Y, et al. Biosimilars: Part 1, Their current status and future direction. Am J Manag Care. 2021;27(6):S125-34. PMID 34115402.
Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatolog Treat. 2015;26(4):299-302. doi: 10.3109/09546634.2015.1054782, PMID 26105205.
Baraliakos X, Braun J. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2018;77(6):963-5. PMID 29352012.
Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R et al.. Secukinumab sustains good efficacy and favorable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033-42. doi: 10.1111/bjd.15706.
Blauvelt A, Papp KA, Griffiths CE, et al. Biosimilars in dermatology: considerations for safe and effective use. J Am Acad Dermatol. 2019;80(6):1557-68.
Farhat F, Torres A, Park W, de Lima Lopes G, Mudad R, Ikpeazu C, et al.. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review. Oncologist. 2018;23(3):346-52. doi: 10.1634/theoncologist.2017-0126. PMID 29284760.
Kimball AB, Gordon KB, Fakharzadeh S, et al. The use of biosimilars in dermatology: a review of the literature. J Eur Acad Dermatol Venereol. 2018;32(12):1788-95.
Puig L, Carrascosa JM, Carretero G, et al. Biosimilars in psoriasis: clinical practice and regulatory perspectives in Latin America. Arch Dermatol Res. 2021;313(5):329-37. PMID 33170434.
Maredia H, Kwatra SG. Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis. J Dermatolog Treat. 2021;32(7):741-4. doi: 10.1080/09546634.2019.1707469. PMID 31900001.
FDA. Biosimilar and interchangeable products [cited Mar 26, 2023]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products.
Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs); October 23, 2009. World Health Organization [cited Aug 22, 2014]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
EMA. Biosimilars in the EU [cited Mar 26, 2023]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilars.
European Medicines Agency. Glossary [cited Mar 10, 2018]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/document_library/landing/glossary.jsp&mid=&startLetter=A.
US Food and Drug Administration. Guidance for Industry: quality considerations in demonstration similarity to a reference protein product. Washington, DC: U.S. Food and Drug Administration; 2012.
European Medicines Agency. Biosimilars in the EU: information guide for healthcare professionals; 2021, March 4. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf [cited 9/5/2023].
Coondoo A, Phiske M, Verma S, Lahiri K. Biologics in dermatology. Indian J Dermatol Venereol Leprol. 2014;80(5):361-75. doi: 10.4103/0378-6323.140287.
Shalom G, Cohen AD, Feldhamer I, Comaneshter D, Freud T, Pavlovsky L. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J Eur Acad Dermatol Venereol. 2020;34(7):1524-8. doi: 10.1111/jdv.16205. PMID 31953883.
FDA. What are generic drugs? Available from: https://www.fda.gov/drugs/generic-drugs/what-are-generic-drugs [cited 9/5/2023].
Mielke J, Jilma B, Koenig F, Jones B. Clinical trials for authorized biosimilars in the European Union: A systematic review. Br J Clin Pharmacol. 2016;82(6):1444-57. doi: 10.1111/bcp.13076, PMID 27580073.
Ventola CL. Biosimilars: part 1: proposed regulatory criteria for FDA approval. P T. 2013;38(5):270-87. PMID 23946620.
Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther. 2012;34(2):400-19. doi: 10.1016/j.clinthera.2011.12.005, PMID 22244050.
Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Cointreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36(5):613-25. doi: 10.1007/s00296-016-3444-0, PMID 26920148.
Diamantopoulos A, Vyzantiadis TA, Papadopoulos D, et al. Cost-effectiveness analysis of biosimilar infliximab (CT-P13) for the treatment of severe psoriasis in Greece. Expert Rev Pharmacoecon Outcomes Res. 2021;21(2):267-73. doi: 10.1080/14737167.2021.1872772.
Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatolog Treat. 2015;26(4):299-302. doi: 10.3109/09546634.2015.1054782, PMID 26105205.
Clemmons NS, Wallace GS, Patel M, Gastañaduy PA. Incidence of Measles in the United States, 2001-2015. JAMA. 2017;318(13):1279-81. doi: 10.1001/jama.2017.9984. PMID 28973240.
Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28(4):363-72. doi: 10.1007/s40259-014-0088-z, PMID 24567263.
Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71(12):1527-36. doi: 10.2165/11593730-000000000-00000, PMID 21861538.
Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015;14(4):261-78. doi: 10.1038/nrd4505. PMID 25743081.
Amutio-Kareaga A, García-Campayo J, Delgado LC, Hermosilla D, Martínez-Taboada C. Improving Communication between Physicians and Their Patients through Mindfulness and Compassion-Based Strategies: a Narrative Review. J Clin Med. 2017;6(3). doi: 10.3390/jcm6030033. PMID 28304333.
Puig L. Biosimilars in dermatology: starting with infliximab. Actas Dermosifiliogr. 2013;104(3):175-80. doi: 10.1016/j.ad.2012.10.002, PMID 23218608.
Okhovat JP, Davine JA, Hawryluk EB, Geller AC Educational brochure impact on postscreening practices of American Academy of Dermatology skin cancer screening participants. J Am Acad Dermatol. 2021;85(6):1616-7. doi: 10.1016/j.jaad.2020.12.030. PMID 33352272.
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP et al.. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-49. doi: 10.1111/bjd.19574. PMID 33000465.
Ventola CL. Biosimilars: part 1: proposed regulatory criteria for FDA approval. P T. 2013;38(5):270-87. PMID 23946620.
Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatolog Treat. 2015;26(4):299-302. doi: 10.3109/09546634.2015.1054782, PMID 26105205.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Ramadan S. Hussein, Salman Bin Dayel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.